within Pharmacolibrary.Drugs.S_SensoryOrgans.S01G_DecongestantsAndAntiallergics.S01GX07_Azelastine;
model Azelastine 
   extends Pharmacolibrary.Drugs.ATC.S.S01GX07;

  annotation(Documentation(
    info ="<html><body><p>Azelastine is a potent second-generation antihistamine with additional anti-inflammatory effects, used mainly for the treatment of allergic conjunctivitis and allergic rhinitis. It is currently approved for ophthalmic and intranasal use globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following ophthalmic administration.</p><h4>References</h4><ol><li><p>Simons, FE, &amp; Simons, KJ (1999). Clinical pharmacology of new histamine H1 receptor antagonists. <i>Clinical pharmacokinetics</i> 36(5) 329–352. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199936050-00003&quot;>10.2165/00003088-199936050-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10384858/&quot;>https://pubmed.ncbi.nlm.nih.gov/10384858</a></p></li><li><p>Beauregard, C, et al., &amp; Yanni, J (2007). Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 23(4) 315–320. DOI:<a href=&quot;https://doi.org/10.1089/jop.2006.0138&quot;>10.1089/jop.2006.0138</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17803429/&quot;>https://pubmed.ncbi.nlm.nih.gov/17803429</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Azelastine;
